The differences between Sorafenib and Lenvatinib include different indications, different side effects, different methods of use and so on.
1. Different indications: Sorafenib is suitable for inoperable advanced hepatocellular carcinoma, inoperable advanced renal carcinoma, recurrent/metastatic differentiated thyroid cancer refractory to radioactive iodine; Lenvatinib is suitable for inoperable hepatocellular carcinoma, advanced renal carcinoma combined with everolimus in which VEGF-targeted therapy has been used in the past, recurrent/metastatic differentiated thyroid cancer refractory to radioactive iodine.
2. Different side effects: the common side effects of Sorafenib include skin reactions of hands and feet, diarrhea, hair loss, rash, hypertension, etc., and the side effects of skin toxicity and hypertension should be noted in the use of Sorafenib; the common side effects of Lenvatinib include hypertension, fatigue, muscle/joint pain, abdominal pain, etc., and the side effects of hypertension should be noted in the use of Sorafenib.
3. Different methods of use: Sorafenib is taken twice a day according to the recommended dosage, and it is recommended to be taken on an empty stomach or with a low-fat or medium-fat diet; Lenvatinib is taken at a fixed time once a day according to the recommended dosage, and it can be taken on an empty stomach or taken with food at the same time.
In addition to the above differences, Sorafenib and Lenvatinib may have other differences, such as different drug ingredients, different manufacturers, etc.; they are prohibited for patients who are allergic to the above drugs, and it is recommended that patients choose the right drug for themselves under the guidance of their doctors.